Celemics

Celemics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Celemics (331920.KQ) as of Nov 2, 2026 is -17.09. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -29.86 — a change of -42.75% (higher).

EV/EBIT

-17.09

YoY

-42.75%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Celemics is 2025 -17.09 . EV/EBIT (Enterprise Value to EBIT) of Celemics was 2024 -29.86 . It decreases by -42.75% higher compared to the previous year.

The Celemics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-13.78 KRW
Jan 1, 2019
-11.23 KRW
Jan 1, 2020
-11.61 KRW
Jan 1, 2021
-9.44 KRW
Jan 1, 2022
-9.91 KRW
Jan 1, 2023
-9.85 KRW
Jan 1, 2024
-29.86 KRW
Jan 1, 2025
-17.09 KRW
The Celemics EV/EBIT history
YEAREV/EBITYoY
-17.09-42.75%
-29.86+203.21%
-9.85-0.63%
-9.91+4.96%
-9.44-18.68%
-11.61+3.37%
-11.23-18.48%
-13.78-14.20%
-16.06—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Celemics Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Celemics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Celemics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Celemics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Celemics grows earnings faster than its peers.

Celemics Stock analysis

What does Celemics do? Celemics Inc is a South Korean company based in Seoul, operating within the Health Care sector, specifically in the Life Sciences Tools & Services industry. The company provides biotechnology services, focusing on the development and sale of target capture kit products. It also offers immune repertoire analysis solutions and next-generation sequencing solutions. Celemics Inc went public through an IPO on August 21, 2020, and currently employs 63 full-time staff. The company's products are sold in both domestic and international markets. Its headquarters are located in Seoul, South Korea, and it maintains a website at www.celemics.com. The firm's primary business activities include the provision of specialized biotechnology services, with an emphasis on innovative tools and solutions for life science research and applications. Celemics Inc has a presence in the Korean market and extends its reach to global customers, supporting various research and diagnostic needs through its technology-driven services. The company's operational focus remains on developing and delivering advanced biotechnology solutions to meet the evolving demands of the life sciences industry. Celemics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celemics stock

EV/EBIT (Enterprise Value to EBIT) of Celemics is -17.09 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Celemics changed from -29.86 to -17.09, representing a -42.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Celemics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Celemics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Celemics

All Key Metrics — Celemics